Center for Infectious Diseases Research, Department of Internal Medicine, National Medical Center, Seoul, Korea.
J Korean Med Sci. 2018 May 14;33(25):e173. doi: 10.3346/jkms.2018.33.e173. eCollection 2018 Jun 18.
The present study investigated prevalence of integrase strand transfer inhibitors (INSTI) resistance mutations in HIV-1-infected antiretroviral therapy (ART)-naïve patients in Korea. From 106 plasma samples, amplification and sequencing of integrase genes was performed, and major or minor mutations were calculated by the Stanford HIV drug resistance mutation interpretation algorithm. No major INSTI resistance mutations were found, and 14 minor mutations were detected in 13 (12.3%) patients. The present data support the recommendation that routine testing for INSTI resistance mutations before starting ART is not necessary.
本研究调查了韩国未经抗逆转录病毒治疗 (ART) 的 HIV-1 感染患者中整合酶链转移抑制剂 (INSTI) 耐药突变的流行情况。从 106 份血浆样本中，对整合酶基因进行了扩增和测序，并通过斯坦福 HIV 耐药突变解释算法计算了主要或次要突变。未发现主要的 INSTI 耐药突变，在 13 名 (12.3%)患者中检测到 14 种次要突变。本数据支持在开始 ART 之前常规检测 INSTI 耐药突变并非必要的建议。
